Chelation for autism spectrum disorder (ASD)

Cochrane Database of Systematic Reviews

Volumn 2015, Issue 5, 2015, Pages

  James, Stephen ^a   Stevenson, Shawn W ^b   Silove, Natalie ^c   Williams, Katrina ^b,d,e  

^a Department of Research ^*  (United States)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c CHILDREN S HOSPITAL AT WESTMEAD   (Australia)

^d ROYAL CHILDREN'S HOSPITAL   (Australia)

^e MURDOCH CHILDREN'S RESEARCH INSTITUTE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CHELATING AGENT; GLUTATHIONE; HEAVY METAL; PLACEBO; SUCCIMER; SKIN CREAM;

AGGRESSIVENESS; AUTISM; CHELATION THERAPY; COMMUNICATION SKILL; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; EVIDENCE BASED MEDICINE; HUMAN; HYPOCALCEMIA; KIDNEY DYSFUNCTION; MULTIPLE CYCLE TREATMENT; MULTIPLE DRUG DOSE; OUTCOME ASSESSMENT; PATIENT SAFETY; PRIORITY JOURNAL; REVIEW; RISK BENEFIT ANALYSIS; SOCIAL BEHAVIOR; SYSTEMATIC REVIEW; TREATMENT DURATION; ADVERSE EFFECTS; BLOOD; CHILD; CHILD DEVELOPMENT DISORDERS, PERVASIVE; FEMALE; MALE; ORAL DRUG ADMINISTRATION; PRESCHOOL CHILD; RANDOMIZED CONTROLLED TRIAL (TOPIC);

ADMINISTRATION, ORAL; CHELATING AGENTS; CHELATION THERAPY; CHILD; CHILD DEVELOPMENT DISORDERS, PERVASIVE; CHILD, PRESCHOOL; FEMALE; GLUTATHIONE; HUMANS; MALE; METALS, HEAVY; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SKIN CREAM; SUCCIMER;

EID: 84945418691     PISSN: 14651858     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD010766.pub2     Document Type: Review

References (64)

1. Adams JB, Baral M, Geis E, Mitchell J, Ingram J, Hensley A, et al. Safety and efficacy of oral DMSA therapy for children with autism spectrum disorders: part a - medical results. BMC Pharmacology & Toxicology 2009;9(16):1-22.
2. Adams JB, Baral M, Geis E, Mitchell J, Ingram J, Hensley A, et al. Safety and efficacy of oral DMSA therapy for children with autism spectrum disorders: part b - behavioral results. BMC Pharmacology & Toxicology 2009;9(17):1-9.
3. NCT00811083 Dimercaptosuccinic acid (DMSA) treatment of children with autism and heavy metal toxicity. http://clinicaltrials.gov/show/NCT00811083 (accessed 19 December 2013).
4. Blaucok-Busch E, Amin OR, Dessoki HH, Rabah T. Efficacy of DMSA therapy in a sample of Arab children with autistic spectrum disorder. Maedica 2012;7(3):214-21.
5. Eppright TD, Sanfacon JA, Horwitz EA. Attention deficit hyperactivity disorder, infantile autism, and elevated blood-lead: a possible relationship. Missouri Medicine 1996;93(3):136-8.
6. Geier DA, Geier MR. A clinical trial of combined anti-androgen and anti-heavy metal therapy in autistic disorders. Neuro Endocrinology Letters 2006;27(6):833-8.
7. Geier DA, Geier MR. A prospective assessment of porphyrins in autistic disorders: a potential marker for heavy metal exposure. Neurotoxicity Research 2006;10(1):57-64.
8. Geier DA, Geier MR. A prospective study of mercury toxicity biomarkers in autistic spectrum disorders. Journal of Toxicology and Environmental Health, Part A 2007;70(20):1723-30.
9. Lonsdale D, Shamberger RJ, Audhya T. Treatment of autism spectrum children with thiamine tetrahydrofurfuryl disulfide: a pilot study. Neuro Endocrinology Letters 2002;23(4):303-8.
10. Nataf R, Skorupka C, Amet L, Lam A, Springbett A, Lathe R. Porphyrinuria in childhood autistic disorder: implications for environmental toxicity. Toxicology and Applied Pharmacology 2006;214(2):99-108.
11. NCT00376194 Mercury chelation to treat autism. http://clinicaltrials.gov/show/NCT00376194 (accessed 19 December 2013).
12. Patel K, Curtis LT. A comprehensive approach to treating autism and attention-deficit hyperactivity disorder: a prepilot study. Journal of Alternative and Complementary Medicine 2007;13(10):1091-7.
13. Adams JB, Audhya T, McDonough-Means S, Rubin RA, Quig D, Geis E, et al. Toxicological status of children with autism vs. neurotypical children and the association with autism severity. Biological Trace Element Research 2013;151(2):171-80.
14. Albizzati A, More L, Di Candia D, Saccani M, Lenti C. Normal concentrations of heavy metals in autistic spectrum disorders. Minerva Pediatrica 2012;64(1):27-31.
15. Amin-Zaki L, Elhassani S, Majeed MA, Clarkson TW, Doherty RA, Greenwood M. Intra-uterine methylmercury poisoning in Iraq. Pediatrics 1974;54(5):587-95.
16. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (DSM-5). 5th Edition. Arlington, VA: American Psychiatric Publishing, 2013.
17. Aschner M, Aschner JL. Mercury neurotoxicity: mechanisms of blood-brain barrier transport. Neuroscience and Biobehavioral Reviews 1990;14(2):169-76.
18. Bakir F, Damluji SF, Amin-Zaki L, Murtadha M, Khalidi A, Al-Rawi NY, et al. Methylmercury poisoning in Iraq. Science 1973;181(4096):230-41.
19. Bernard S, Enayati A, Redwood L, Roger H, Binstock T. Autism: a novel form of mercury poisoning. Medical Hypotheses 2001;56(4):462-71.
20. Bradstreet J, Geier DA, Kartzinel JJ, Adams JB, Geier MR. A case-control study of mercury burden in children with autistic spectrum disorders. Journal of American Physicians and Surgeons 2003;8(3):76-9.
21. Brown MJ, Willis T, Omalu B, Leiker R. Deaths resulting from hypocalcemia after administration of edetate disodium: 2003-2005. Pediatrics 2006;118(2):e534-6.
22. Cheuk DKL, Wong V, Chen WX. Acupuncture for autism spectrum disorders (ASD). Cochrane Database of Systematic Reviews 2011, Issue 9. [DOI: 10.1002/14651858.CD007849.pub2]
23. Christon LM, Mackintosh VH, Myers BJ. Use of complementary and alternative medicine (CAM) treatments by parents of children with autism spectrum disorders. Research in Autism Spectrum Disorders 2010;4(2):249-59.
24. Cohen DJ, Johnson WT, Caparulo BK. Pica and elevated blood lead level in autistic and atypical children. American Journal of Diseases of Children 1976;130(1):47-8.
25. Cohen DJ, Paul R, Anderson GM, Harcherik DF. Blood lead in autistic children. Lancet 1982;320(8289):94-5.
26. Counter SA, Buchanan LH. Mercury exposure in children: a review. Toxicology and Applied Pharmacology 2004;198(2):209-30.
27. Dans AL, Tan FN, Villarruz-Sulit EC. Chelation therapy for atherosclerotic cardiovascular disease. Cochrane Database of Systematic Reviews 2002, Issue 4. [DOI: 10.1002/14651858.CD002785]
28. Davis TN, O'Reilly M, Kang S, Lang R, Rispoli M, Sigafoos J, et al. Chelation treatment for autism spectrum disorders: a systematic review. Research in Autism Spectrum Disorders 2013;7(1):49-55.
29. Deth R, Muratore C, Benzecry J, Power-Charnitsky V, Waly M. How environmental and genetic factors combine to cause autism: a redox/methylation hypothesis. Neurotoxicology 2008;29(1):190-201.
30. Drugs.com Drug information online. www.drugs.com/drug-class/chelating-agents.html (accessed 10 January 2012).
31. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997;315(7109):629-34.
32. Ernst E. Chelation therapy for coronary heart disease: an overview of all clinical investigations. American Heart Journal 2000;140(1):139-41.
33. Garrecht M, Austin DW. The plausibility of a role for mercury in the etiology of autism: a cellular perspective. Toxicological and Environmental Chemistry 2011;93(5-6):1251-73.
34. Geretsegger M, Elefant C, Mössler KA, Gold C. Music therapy for people with autism spectrum disorder. Cochrane Database of Systematic Reviews 2014, Issue 6. [DOI: 10.1002/14651858.CD004381.pub3]
35. Goin-Kochel RP, Mackintosh VH, Myers BJ. Parental reports on the efficacy of treatments and therapies for their children with autism spectrum disorders. Research in Autism Spectrum Disorders 2009;3(2):528-37.
36. Goldman LR, Shannon MW, American Academy of Pediatrics: Committee on Environmental Health. Technical report: mercury in the environment: implications for pediatricians. Pediatrics 2001;108(1):197-205.
37. Golnik AE, Ireland M. Complementary alternative medicine for children with autism: a physician survey. Journal of Autism and Developmental Disorders 2009;39(7):996-1005.
38. Grandjean P, Weihe P, White RF, Debes F, Araki S, Yokoyama K, et al. Cognitive deficit in 7-year-old children with prenatal exposure to methylmercury. Neurotoxicology and Teratology 1997;19(6):417-28.
39. Green VA, Pituch KA, Itchon J, Choi A, O'Reilly M, Sigafoos J. Internet survey of treatments used by parents of children with autism. Research in Developmental Disabilities 2006;27(1):70-84.
40. Hallmayer J, Cleveland S, Torres A, Phillips J, Cohen B, Torigoe T, et al. Genetic heritability and shared environmental factors among twin pairs with autism. Archives of General Psychiatry 2011;68(11):1095-102.
41. Hanson E, Kalish L, Bunce E, Curtis C, McDaniel S, Ware J, et al. Use of complementary and alternative medicine among children diagnosed with autism spectrum disorder. Journal of Autism and Developmental Disorders 2007;37(4):629-36.
42. Hedge ML, Bharathi P, Suram A, Venugopal C, Jagannathan R, Poddar P, et al. Challenges associated with metal chelation therapy in Alzheimer's disease. Journal of Alzheimer's Disease 2009;17(3):457-68.
43. Hertz-Picciotto I, Green PG, Delwiche L, Hansen R, Walker C, Pessah LN. Blood mercury concentrations in CHARGE study children with and without autism. Environmental Health Perspectives 2010;118(1):161-6.
44. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
45. Holmes AS, Blaxill MF, Haley BE. Reduced levels of mercury in first baby haircuts of autistic children. International Journal of Toxicology 2003;22(4):277-85.
46. James S, Montgomery P, Williams K. Omega-3 fatty acids supplementation for autism spectrum disorders (ASD). Cochrane Database of Systematic Reviews 2011, Issue 11. [DOI: 10.1002/14651858.CD007992.pub2]
47. Kern JK, Grannemann BD, Trivedi MH, Adams JB. Sulfhydryl-reactive metals in autism. Journal of Toxicology and Environmental Health, Part A 2007;70(8):715-21.
48. Kosnett MJ. Chelation for heavy metals (arsenic, lead, and mercury): protective or perilous?. Clinical Pharmacology & Therapeutics 2010;88(3):412-5.
49. Lecavalier L. Behavioral and emotional problems in young people with pervasive developmental disorders: relative prevalence, effects of subject characteristics, and empirical classification. Journal of Autism and Developmental Disorders 2006;36(8):1101-14.
50. Levy SE, Hyman SL. Use of complementary and alternative treatments for children with autistic spectrum disorders is increasing. Pediatric Annals 2003;32(10):685-91.
51. Liu J, Goyer RA, Waalkes MP. Toxic effects of metals. In: Klaassen CD editor(s). Casarett & Doull's Toxicology: The Basic Science of Poisons. 7th Edition. New York: McGraw-Hill, 2008:931-79.
52. Millward C, Ferriter M, Calver SJ, Connell-Jones GG. Gluten- and casein-free diets for autistic spectrum disorder. Cochrane Database of Systematic Reviews 2008, Issue 2. [DOI: 10.1002/14651858.CD003498.pub3]
53. Mitka M. Chelation therapy trials halted. JAMA 2008;300(19):2236.
54. Morgan BW, Kori S, Thomas JD. Adverse effects in 5 patients receiving EDTA at an outpatient chelation clinic. Veterinary and Human Toxicology 2002;44(5):274-6.
55. Nye C, Brice A. Combined vitamin B6-magnesium treatment in autism spectrum disorder. Cochrane Database of Systematic Reviews 2005, Issue 4. [DOI: 10.1002/14651858.CD003497.pub2]
56. Osterloh J, Becker CE. Pharmacokinetics of CaNa2EDTA and chelation of lead in renal failure. Clinical Pharmacology and Therapeutics 1986;40(6):686-93.
57. Rahbar MH, Samms-Vaughan M, Loveland KA, Ardjomand-Hessabi M, Chen Z, Bressler J, et al. Seafood consumption and blood and blood mercury concentrations in Jamaican children with and without autism spectrum disorders. Neurotoxicity Research 2013;23(1):22-38.
58. Semple S, Hewton C, Paterson F, Angley M. Complementary medicine products used in autism - evidence for efficacy and safety. In: Williams T editor(s). Autism Spectrum Disorders - From Genes to Environment. Rijeka, Croatia: InTech, 2011:77-100.
59. Shattuck PT, Seltzer MM, Greenberg JS, Orsmond GI, Bolt D, Kring S, et al. Change in autism symptoms and maladaptive behaviors in adolescents and adults with an autism spectrum disorder. Journal of Autism and Developmental Disorders 2007;37(9):1735-47.
60. Sinha Y, Silove N, Williams K. Letters. Chelation therapy and autism. BMJ 2006;333(7571):756.
61. Sinha Y, Silove N, Hayen A, Williams K. Auditory integration training and other sound therapies for autism spectrum disorders (ASD). Cochrane Database of Systematic Reviews 2011, Issue 12. [DOI: 10.1002/14651858.CD003681.pub3]
62. Vamnes JS, Eide R, Isrenn R, Hol PJ, Gjerdet NR. Diagnostic value of a chelating agent in patients with symptoms allegedly caused by amalgam fillings. Journal of Dental Research 2000;79(3):868-74.
63. Zecavati N, Spence SJ. Neurometabolic disorders and dysfunction in autism spectrum disorders. Current Neurology and Neuroscience Reports 2009;9(2):129-36.
64. James S, Williams K, Silove N, Stevenson SW. Chelation for autism spectrum disorder (ASD). Cochrane Database of Systematic Reviews 2013, Issue 10. [DOI: 10.1002/14651858.CD010766]